A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients
Status:
Withdrawn
Trial end date:
2021-08-18
Target enrollment:
Participant gender:
Summary
This is a randomized study to assess safety, pharmacokinetics, immunogenicity, and efficacy
of BAT2020 in hospitalized patients infected with COVID-19. This study is composed of 2
Parts: a single ascending dose (Part 1) and single dose(s) tested in parallel with a
double-blind, placebo-controlled design (Part 2). Patients also will receive best available
standard of care (SOC) treatment. A data and safety monitoring board (DSMB) will be set up
for the study.